Bifogade filer
PDF
Kurs
-0,95%
Likviditet
4,47 MSEK
Kalender
| Tid* | ||
| 2025-10-23 | 07:00 | Kvartalsrapport 2025-Q3 |
| 2025-07-17 | 07:00 | Kvartalsrapport 2025-Q2 |
| 2025-04-17 | 07:00 | Kvartalsrapport 2025-Q1 |
| 2025-02-06 | 07:00 | Bokslutskommuniké 2024 |
| 2024-10-17 | - | Kvartalsrapport 2024-Q3 |
| 2024-07-18 | - | Kvartalsrapport 2024-Q2 |
| 2024-06-28 | - | X-dag ordinarie utdelning HNSA 0.00 SEK |
| 2024-06-27 | - | Årsstämma |
| 2024-04-18 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-02 | - | Bokslutskommuniké 2023 |
| 2023-10-26 | - | Kvartalsrapport 2023-Q3 |
| 2023-07-20 | - | Kvartalsrapport 2023-Q2 |
| 2023-06-15 | - | X-dag ordinarie utdelning HNSA 0.00 SEK |
| 2023-06-14 | - | Årsstämma |
| 2023-04-20 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-02 | - | Bokslutskommuniké 2022 |
| 2022-10-20 | - | Kvartalsrapport 2022-Q3 |
| 2022-07-19 | - | Kvartalsrapport 2022-Q2 |
| 2022-06-17 | - | X-dag ordinarie utdelning HNSA 0.00 SEK |
| 2022-06-16 | - | Årsstämma |
| 2022-04-21 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-03 | - | Bokslutskommuniké 2021 |
| 2021-10-21 | - | Kvartalsrapport 2021-Q3 |
| 2021-07-15 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-14 | - | X-dag ordinarie utdelning HNSA 0.00 SEK |
| 2021-05-12 | - | Årsstämma |
| 2021-04-22 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-04 | - | Bokslutskommuniké 2020 |
| 2020-10-22 | - | Kvartalsrapport 2020-Q3 |
| 2020-07-16 | - | Kvartalsrapport 2020-Q2 |
| 2020-06-24 | - | X-dag ordinarie utdelning HNSA 0.00 SEK |
| 2020-06-23 | - | Årsstämma |
| 2020-04-28 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-06 | - | Bokslutskommuniké 2019 |
| 2019-10-31 | - | Kvartalsrapport 2019-Q3 |
| 2019-07-18 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-23 | - | X-dag ordinarie utdelning HNSA 0.00 SEK |
| 2019-05-22 | - | Årsstämma |
| 2019-04-29 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-08 | - | Bokslutskommuniké 2018 |
| 2018-11-01 | - | Kvartalsrapport 2018-Q3 |
| 2018-07-19 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-30 | - | X-dag ordinarie utdelning HNSA 0.00 SEK |
| 2018-05-29 | - | Årsstämma |
| 2018-04-25 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-14 | - | Bokslutskommuniké 2017 |
| 2017-12-22 | - | Extra Bolagsstämma 2017 |
| 2017-11-14 | - | Kvartalsrapport 2017-Q3 |
| 2017-07-20 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-24 | - | X-dag ordinarie utdelning HNSA 0.00 SEK |
| 2017-05-23 | - | Årsstämma |
| 2017-04-26 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-15 | - | Bokslutskommuniké 2016 |
| 2016-11-21 | - | Extra Bolagsstämma 2016 |
| 2016-11-09 | - | Kvartalsrapport 2016-Q3 |
| 2016-07-21 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-11 | - | Årsstämma |
| 2016-04-28 | - | X-dag ordinarie utdelning HNSA 0.00 SEK |
| 2016-04-27 | - | Kvartalsrapport 2016-Q1 |
| 2016-02-18 | - | Bokslutskommuniké 2015 |
| 2015-10-28 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-25 | - | Kvartalsrapport 2015-Q2 |
| 2015-04-17 | - | X-dag ordinarie utdelning HNSA 0.00 SEK |
| 2015-04-16 | - | Årsstämma |
| 2015-04-16 | - | Kvartalsrapport 2015-Q1 |
| 2015-02-05 | - | Bokslutskommuniké 2014 |
| 2014-07-25 | - | Kvartalsrapport 2014-Q2 |
| 2014-06-04 | - | X-dag ordinarie utdelning HNSA 0.00 SEK |
| 2014-06-03 | - | Årsstämma |
| 2014-03-05 | - | Extra Bolagsstämma 2014 |
| 2014-02-05 | - | Bokslutskommuniké 2013 |
| 2013-07-25 | - | Kvartalsrapport 2013-Q2 |
| 2013-05-07 | - | X-dag ordinarie utdelning HNSA 0.00 SEK |
| 2013-05-06 | - | Årsstämma |
| 2013-02-07 | - | Bokslutskommuniké 2012 |
| 2012-09-28 | - | Kapitalmarknadsdag 2012 |
| 2012-07-26 | - | Kvartalsrapport 2012-Q2 |
| 2012-05-14 | - | Årsstämma |
| 2012-02-09 | - | Bokslutskommuniké 2011 |
| 2012-01-09 | - | Extra Bolagsstämma 2011 |
| 2011-07-28 | - | Kvartalsrapport 2011-Q2 |
| 2011-05-12 | - | Årsstämma |
| 2011-05-06 | - | X-dag ordinarie utdelning HNSA 0.00 SEK |
| 2010-04-30 | - | X-dag ordinarie utdelning HNSA 0.00 SEK |
| 2010-02-10 | - | Bokslutskommuniké 2009 |
| 2009-07-30 | - | Kvartalsrapport 2009-Q1 |
| 2009-05-12 | - | Kvartalsrapport 2009-Q2 |
| 2009-04-30 | - | X-dag ordinarie utdelning HNSA 0.00 SEK |
| 2009-04-29 | - | Årsstämma |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Mid Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Lund, Sweden, 30 October, 2024. Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA) today announced it will attend Truist Securities BioPharma Symposium on November 7 in New York, NY. Hitto Kaufmann, Chief R&D Officer at the Company will participate in a panel discussion entitled, `Inflammatory Insights: Advancing Novel Therapeutics Across Autoimmune and Inflammatory Indications' on Thursday November 7th from 10:30 to 11:20 AM EST.
Recently Hansa conducted a 12-month follow up analysis of data from the NICE-01 trial of HNSA-5487, the company's next generation molecule. The analysis demonstrates that HNSA-5487 can robustly and very rapidly reduce IgG levels, has redosing potential, and a favorable safety and tolerability profile.
Hansa management will be available for meetings at the conference. If you are interested in meeting with the management team, please contact Hansa Biopharma at ir@hansabiopharma.com.
To learn more about Hansa Biopharma see the latest Corporate Presentation here (https://www.hansabiopharma.com/files/Presentations/2024/HansaBiopharma_CorporatePresentation_Oct2024_3.pdf). The latest investor presentation can be viewed here (https://www.hansabiopharma.com/files/FinancialReports/2024/20241017_Q3-24_EarningsPresentation.pdf).
--- ENDS ---
Contacts for more information:
Evan Ballantyne, Chief Financial Officer
IR@hansabiopharma.com
Stephanie Kenney, VP Global Corporate Affairs
media@hansabiopharma.com
About Hansa Biopharma
Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions. Hansa Biopharma has developed a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients. Hansa Biopharma has a rich and expanding research and development program based on the Company's proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in transplantation, autoimmune diseases, gene therapy and cancer. Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at www.hansabiopharma.com and follow us on LinkedIn (https://www.linkedin.com/company/hansa-medical-ab/).
©2024 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and IDEFIRIX flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All rights reserved.